Article

McKesson to Pay $190 Million to Resolve False-Claims Allegations

In a news release, the U.S. Justice Department said that states can separately negotiate resolutions with McKesson pertaining to claims based on the states' shares of Medicaid overpayments.

Story in progress.

Read this story: http://hcp.lv/KdT9b1

Source: ModernHealthcare.com

McKesson Corp., a San Francisco-based drug wholesaler and health information technology provider, will pay the U.S. more than $190 million to resolve claims it reported inflated prices for several prescription drugs, causing Medicaid to overpay for the drugs.

Related Videos
Fulling and Cournoyer
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Tiara Green, MSEd
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
Related Content
CH LogoCenter for Biosimilars Logo